AIRCORT ® Budesonide

AIRCORT ® is a Budesonide based drug

THERAPEUTIC GROUP: Rhinological - Nasal decongestants and other preparations for topical use

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications AIRCORT ® Budesonide

AIRCORT ® is indicated for the treatment of seasonal allergic rhinitis, perennial and non-allergic allergy sufferers. This drug is also used in the treatment of nasal polyposis and in the prophylaxis of its recurrences after polypectomy.

Action mechanism AIRCORT ® Budesonide

AIRCORT ® is a drug based on Budesonide, an active ingredient belonging to the category of glucorticoids with a high local anti-inflammatory activity.

In fact, taken topically it is able to promptly remodulate the inflammatory microenvironment, reducing the expression of inflammatory mediators and indirectly inhibiting the recall of inflammatory cellular elements, often the cause of tissue damage.

In addition to effective anti-inflammatory activity, Budesonide has proved useful in controlling allergic symptoms, probably by controlling the presence of molecular mediators with vasodilatory and edemigenic activity.

Despite the proportion of the drug absorbed following nasal administration, it is significant, the first-pass metabolism to which it is subjected, significantly reduces the risk of systemic side effects, classically linked to oral corticosteroid therapy.

Studies carried out and clinical efficacy

ANTI-INFLAMMATORY EFFECTIVENESS OF BUDESONIDE

Clin Exp Allergy. 2009 Jan; 39 (1): 81-8. doi: 10.1111 / j.1365-2222.2008.03144.x. Epub 2008 Nov 26.

Valera FC, Queiroz R, Scrideli C, Tone LG, Anselmo-Lima WT.

Study demonstrating that topical administration of Budesonide can reduce the expression of inflammatory cytokines such as TNF alpha, i-1 and adhesion molecules, guaranteeing a significant reduction in the inflammatory infiltrate and significantly improving the clinical course of nasal polyposis .

STATE OF THE ART IN THE TREATMENT OF NASAL POLYPOSIS

Am J Rhinol Allergy. 2011 Sep-Oct; 25 (5): 291-8. doi: 10.2500 / ajra.2011.25.3681.

Aouad RK, Chiu AG.

2011 study, which highlights the importance of Budesonide and other topical anti-inflammatories in the treatment and prevention of recurrences of nasal polyposis.

BUDESONIDE IN ASMATIC PATIENTS

Thorax. 2013 Oct 3. doi: 10.1136 / thoraxjnl-2013-203557. [Epub ahead of print]

Method of use and dosage

AIRCORT ®

Nasal spray from 1 or 2 mg of Budesonide per ml of solution.

The dosage schedule and duration of therapy should be defined by the physician based on the patient's general health condition and the severity of his / her clinical picture.

In general, however, in the treatment of rhinitis it is recommended to apply 50 mcg of drug per nostril twice a day; these dosages doubling in the treatment and prevention of nasal polyps.

Warnings AIRCORT ® Budesonide

AIRCORT ® therapy must necessarily be defined and supervised by your doctor, given the potential side effects of corticosteroids even when used topically.

Prolonged use and high doses of this drug could in fact lead to the appearance of systemic adverse reactions of severe clinical entity, such as hypertension, reduction of bone mineral density, hyperactivity, sleep disturbances and anxiety especially in the youngest.

Particular caution in the use of AIRCORT ® should instead be applied in patients with nasal ulcers or with concomitant superimposition of nasal infections of a viral or fungal nature.

The use of this drug, without therapeutic needs, constitutes doping and can determine positivity to doping tests also following the use of therapeutic doses.

PREGNANCY AND BREASTFEEDING

The use of AIRCORT ® during pregnancy and in the subsequent period of breastfeeding is generally contraindicated given the presence of studies that report the appearance of teratogenic effects in unborn children.

Interactions

Studies show that the simultaneous administration of Cimetidine can alter the normal pharmacokinetic characteristics of Budesonide.

Contraindications AIRCORT ® Budesonide

The use of AIRCORT ® is contraindicated in patients with hypersensitivity to the active ingredient or to one of its excipients.

Undesirable effects - Side effects

The use of AIRCORT ®, especially when continued for a long time, could determine the appearance of local side effects such as hives, rash, nasal dryness and itching.

Fortunately, the incidence of severe and clinically relevant systemic side effects is rarer.